logo-loader
viewAmphion Innovations PLC

Amphion Innovations now private after AIM de-listing

Snapshot

Amphion Innovations provides “concentrated but well-managed portfolio” in high growth sectors

Amphion Innovations PLC -

Quick facts: Amphion Innovations PLC

Price: - -

AIM:AMP
Market: AIM
Market Cap: -
Follow
  • Investment firm focused on medical and technology sectors

  • Concentrated portfolio of companies

  • Recently delisted from Aim

 

What Amphion does

Amphion Innovations PLC (LON:AMP) is an investment company that focuses on helping build companies in the medical and technology sectors.

The firm currently has shareholdings in seven partner companies that are developing technologies targeting what it says are “substantial commercial marketplaces”.

.

What Amphion owns

The company has stakes in six partner companies;

1. Axcess International – 15.07% stake – provides wireless systems that help monitor business activity in real-time in sectors such as transport and security

2. FireStar Software – 11.86% stake – develops software the helps companies to integrate and exchange data electronically in a private, secured structure

3.  PrivateMarkets – 25.33% stake – an online marketplace that links buyers and sellers of physical commodities such as gold and copper

4. WellGen – 24.34% stake – develops foods designed to help treat inflammation-based illnesses. The company also has a proprietary black tea extract that has been demonstrated to improve performance and recovery benefits such as a reduction in muscle soreness and reduced recovery time

5. DataTern – 100% stake – a company established for Amphion to commercialise intellectual properties that originate from its portfolio companies

6. Motif Bio PLC (LON:MTFB) –  below 3% – an antibiotic developer focusing on diseases caused by drug-resistant bacteria

 

Inflexion points

  • Amphion recently paid back a loan facility through sale of its stake in listed group Polarean
  • Shares delisted from AIM at end of 2019
  • Company is looking for an additional source of finance

 

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

2 days, 14 hours ago

2 min read